<DOC>
	<DOCNO>NCT00875979</DOCNO>
	<brief_summary>This multi-institutional , multinational , open-label , single-arm Phase Ib/II study design evaluate safety , tolerability , pharmacokinetics , efficacy trastuzumab emtansine ( trastuzumab-MCC-DM1 ) administer intravenous ( IV ) infusion combination pertuzumab patient human epidermal growth factor receptor-2 ( HER2 ) -positive locally advanced metastatic breast cancer previously receive trastuzumab .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine ( Trastuzumab-MCC-DM1 , T-DM1 ) Combination With Pertuzumab Administered Patients With Human Epidermal Growth Factor Receptor-2 ( HER2 ) -Positive Locally Advanced Metastatic Breast Cancer Who Have Previously Received Trastuzumab</brief_title>
	<detailed_description>There 2 phase study , Dose Escalation phase ( Phase 1b ) Dose Expansion phase ( Phase 2a ) . In Dose Escalation phase , 3 patient enrol first dose level ( 3.0 mg/kg trastuzumab emtansine ) 6 patient enrolled second dose level ( 3.6 mg/kg trastuzumab emtansine ) . An additional 58 patient enrol 3.6 mg/kg trastuzumab emtansine dose level Dose Expansion phase ( Phase 2a ) study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Histologically document human epidermal growth factor receptor 2 ( HER2 ) positive locally advanced metastatic breast cancer . Tumor tissue block 1520 unstained tissue slide confirmatory central laboratory HER2 status test exploratory assessment . Prior trastuzumab line therapy . No prior trastuzumab emtansine ( TDM1 ) pertuzumab therapy . Measurable disease . For woman childbearing potential , agreement use effective form contraception continue use duration study . Life expectancy ≥ 90 day . Less 21 day since last antitumor therapy , include chemotherapy , biologic , experimental , immune , hormonal , radiotherapy treatment breast cancer , follow exception : Hormonereplacement therapy oral contraceptive ; palliative radiation therapy involve ≤ 25 % marrowbearing bone administer ≥ 14 day prior first study treatment . History intolerance hypersensitivity trastuzumab and/or adverse event relate trastuzumab result trastuzumab permanently discontinue . Peripheral neuropathy Grade ≥ 2 . History clinically significant cardiac dysfunction . Current severe , uncontrolled systemic disease , eg , clinically significant cardiovascular , pulmonary , metabolic disease . Brain metastasis untreated , progressive , required type therapy control symptom brain metastasis within 60 day first study treatment . History malignancy within last 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , malignancy similar expect curative outcome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>MBC</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2+</keyword>
	<keyword>HER2+ breast cancer</keyword>
	<keyword>HER2 positive breast cancer</keyword>
	<keyword>herceptin</keyword>
	<keyword>Trastuzumab emtansine</keyword>
</DOC>